




مركز الكويت لمكافحة السرطان  
Kuwait Cancer Control Center

# pemBROLizumab (Keytruda®)



\* P M B - 0 0 0 0 0 - 0 2 - C N - M L \*



Ministry of Health

**Name:**

**File #:**

**Ht (cm):**

**Nationality:**

**Civil ID:**

**Wt (Kg):**

**Gender/Age:**

**DOB:**

**BSA (m<sup>2</sup>):**

**Approved indication(s):** - Multiple malignancies: Locally advanced or metastatic NSCLC / urothelial carcinoma / head & neck cancers / melanoma / renal cell carcinoma / microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) GIT tumors / Merkel cell carcinoma.

**Central line:**  Available  NA

**Allergies:**  NKA  Yes, specify; \_\_\_\_\_

**Parameters:** Initiate treatment only if ANC ≥ 1000; HB ≥ 80; Plt ≥ 100,000; CrCl > 45 ml/min

**Pre-treatment Medications:** (30 min before starting treatment)

Chlorphenamine 10 mg PO/IV

### Standard Protocol:

DRUG	DOSE	INSTRUCTIONS	DAYS
pemBROLizumab	200 mg	IV in 250 mL NS over 30 min.	D1
<b>To be repeated every 3 weeks until disease progression or intolerable toxicity.</b>			

### Treatment Description:

Cycle	DATE	pemBROLizumab	Physician	Consultant
C# __				

**Comments:**